Biogen completes acquisition of RayThera, advancing immunology pipeline with Phase 1 drug program.
Biogen has finalized its acquisition of RayThera Inc., a biotech company specializing in small-molecule therapies for immunology. This deal enhances Biogen's immunology portfolio by adding multiple assets aimed at treating immune-related diseases. Th...
